Intravitreal injections of anti-VEGF agents have become an important tool in the management of some of the most common retinal and choroidal neovascular diseases. Adverse effects are uncommon ...

Masking during intravitreal anti-VEGF injections was associated with a similar ... with higher odds of developing the inflammatory eye condition, according to research presented at the 2024 ...

which can damage the eye. Anti-VEGF medications block the production of the protein and can improve vision. However, they currently need to be administered via an intravitreal injection ...

Despite the severe vision loss often experienced by people with wet AMD, less than half of patients treated with monthly eye injections, known as anti-VEGF therapies, show any major vision ...

Despite the severe vision loss often experienced by people with wet AMD, less than half of patients treated with monthly eye injections of anti-VEGF therapies show any major vision improvements.

Both LUNA and OPTIC were designed to assess a broad wet AMD population, including hard-to-treat patients with severe disease ...

These findings could explain why fewer than half of patients who receive monthly anti-VEGF eye injections wind up showing any major improvements in their vision, researchers said. “We have ...

LUNA Phase 2 Trial and OPTIC First-in-Human Trial - Background and Baseline Prior Anti-VEGF Injections LUNA is an ongoing double-masked, randomized Phase 2 trial. 60 patients with wet AMD were ...

The global macular degeneration treatment market is poised for significant growth, projected to expand from USD 9.1 billion ...